Glancy Prongay & Murray LLP announces that it is investigating potential
claims on behalf of investors of Insulet Corp. (“Insulet” or the
“Company”) (NASDAQ: PODD) concerning the Company’s and its officers’
possible violations of federal securities laws.
Insulet, the maker of insulin infusion systems, posted results on April
30, 2015, after the market close, that fell below analyst expectations.
The Company posted quarterly revenue of $61.2 million in the period,
which did not meet an analysts survey expecting $68.3 million. For the
current quarter ending in June, Insulet said it expects revenue in the
range of $67 million to $70 million. Insulet also provided full-year
revenue projections in the range of $305 million to $320 million.
On this news Insulet shares fell over 18%, or $5.65 per share in
after-hours trading on April 30, 2015.
If you purchased shares of Insulet between February 2013 through April
30, 2015, have information or would like to learn more about these
claims, or have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact Lesley
Portnoy, of Glancy Prongay & Murray LLP , 1925 Century Park East, Suite
2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at
888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2015